The chances of surviving breast cancer are high, especially when it’s caught early. The overall 5-year relative survival rate for women diagnosed with breast cancer in the United States is above 90%, and for cancer that hasn’t spread beyond the breast, that number reaches 100%. These statistics have improved dramatically over the past three decades, with breast cancer death rates dropping 44% from their peak in 1989 to 2022.
That said, survival varies significantly depending on how far the cancer has spread, the biological subtype, and a person’s age at diagnosis. Here’s what those numbers actually look like.
Survival Rates by Stage at Diagnosis
Stage at diagnosis is the single biggest factor in breast cancer survival. The National Cancer Institute’s SEER program tracks 5-year relative survival, which compares women with breast cancer to women in the general population of the same age. It’s a more accurate measure than raw survival percentages because it filters out deaths from other causes.
Based on data from 2016 to 2022, the 5-year relative survival rates break down like this:
- Localized (cancer confined to the breast): 100%
- Regional (cancer has spread to nearby lymph nodes): 87.5%
- Distant (cancer has metastasized to other organs): 33.8%
“Localized” covers most Stage I and some Stage II cancers, while “regional” includes later Stage II and Stage III. The vast majority of breast cancers are caught at the localized or regional stage, which is a large part of why overall survival numbers are so favorable. Routine mammography screening plays a direct role here, catching tumors before they have a chance to spread.
How Cancer Subtype Affects Your Outlook
Not all breast cancers behave the same way. Tumors are classified by whether they have receptors for estrogen, progesterone, or a protein called HER2. These receptors determine how the cancer grows and, importantly, which treatments can target it.
Hormone receptor-positive cancers (the most common type) tend to grow more slowly and respond well to therapies that block estrogen. HER2-positive cancers were once considered especially aggressive, but targeted therapies developed over the past two decades have changed the picture so significantly that even stage IV HER2-positive disease is now considered potentially curable in some cases. The 5-year survival rate for distant HER2-positive breast cancer (with hormone receptors) is 45.6%, the highest of any metastatic subtype.
Triple-negative breast cancer, which lacks all three receptor types, has fewer targeted treatment options and tends to be more aggressive. The numbers reflect this:
- Localized triple-negative: 92% five-year survival
- Regional triple-negative: 67%
- Distant triple-negative: 15%
- All stages combined: 78%
Compare that distant triple-negative figure of 15% to the 45.6% for HER2-positive hormone receptor-positive cancers, and you can see how much subtype matters once cancer has spread. At the localized stage, the gap narrows considerably: 92% versus 100%.
Metastatic Breast Cancer Survival
A diagnosis of stage IV (metastatic) breast cancer, where cancer has spread to the bones, lungs, liver, or brain, carries the most serious prognosis. The overall 5-year relative survival rate for distant breast cancer is around 31 to 34%, depending on the data set and years measured.
But that number varies widely by subtype. The National Cancer Institute breaks it down:
- HR-positive/HER2-negative (the most common metastatic subtype): 34.0%
- HR-positive/HER2-positive: 45.6%
- HR-negative/HER2-positive: 39.5%
- Triple-negative: 12.8%
These figures reflect women diagnosed between 2013 and 2019, and newer treatments approved since then may push some of these numbers higher. Many women with metastatic breast cancer now live years or even a decade or more with ongoing treatment, particularly those with hormone receptor-positive disease.
Age at Diagnosis
Women diagnosed under age 40 tend to have more aggressive tumor biology, and their cancers are more likely to be diagnosed at a later stage. A study published in JCO Global Oncology found that for young women (40 and under), the 5-year overall survival was 89.4%, dropping to 76% at 10 years.
Stage made a major difference even within this younger group. Those with stage I or II disease had a 96% five-year survival rate and 87.1% at 10 years. Stage III dropped to 88.3% at five years and 68.7% at 10 years. Even among young women with stage IV cancer, 64.5% were alive at five years, though that fell to 48.4% at the 10-year mark.
Women diagnosed between ages 50 and 69 generally have the best outcomes, partly because screening catches their cancers earlier and partly because their tumors are more likely to be hormone receptor-positive, the most treatable subtype.
Recurrence Risk After Treatment
Surviving the initial treatment doesn’t eliminate the possibility of cancer returning. But for early-stage breast cancer, the odds are strongly in your favor. Women treated for stage 0, I, or II breast cancer have up to a 95% chance of remaining cancer-free at 5 years, according to Mayo Clinic.
Recurrence risk doesn’t disappear after the five-year mark, though. Hormone receptor-positive cancers in particular can recur 10, 15, or even 20 years after the original diagnosis. This is why many women with hormone receptor-positive disease take hormone-blocking medication for 5 to 10 years after treatment. Triple-negative breast cancers, by contrast, are more likely to recur within the first 3 to 5 years, with the risk dropping substantially after that window.
Why Survival Rates Keep Improving
The 44% decline in breast cancer death rates since 1989 reflects real, compounding progress on multiple fronts. Mammography screening became widespread in the 1990s, catching cancers smaller and earlier. Hormone-blocking therapies became standard for receptor-positive disease. Targeted therapies for HER2-positive cancers transformed what was once one of the deadliest subtypes into one of the most treatable. More recently, immunotherapy has begun showing results for triple-negative cases.
Survival statistics are also, by their nature, backward-looking. The 5-year survival rates published today reflect women diagnosed years ago, treated with older protocols. A woman diagnosed today benefits from treatments that won’t show up in population-level statistics for another half decade. That’s worth keeping in mind when reading any survival number: your actual odds are likely somewhat better than what the data currently shows.